Metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose transport protein-2 (SGLT-2) inhibitors, which are widely used diabetes treatments, have various effects, including anti-inflammatory properties that impact a range of conditions [29–31]. This evidence concerns the gene DPP4 and diabetes mellitus.